Abstract
Prenatal genetic diagnosis (PGD) options are rapidly evolving to include genome/exome sequencing (GS/ES), molecular panels, and single-gene cell-free DNA (NIPT) in addition to established karyotype/microarray. However, there is significant regional variance in test uptake (patient desire, insurance). We studied PGD uptake in cases of suspected fetal skeletal dysplasia over 10 years in the southeast US.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
